We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Eve4.2

Everolimus Research

Mostly mechanism / observational

190 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Everolimus studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2008–2026 with a typical study size of 410 participants.

Based on 190 studies · 24 meta-analyses · 157 RCTs · 2,803 total participants

Confidence

High confidence

By outcome

Oncology (approved use)
Mostly mechanism / observational63 studies
Safety profile
Mostly mechanism / observational17 studies
Aging & healthspan (emerging)
Mostly mechanism / observational11 studies
Immune & vaccine responseRandomized trials showed low-dose everolimus improved influenza-vaccine response and a TORC1-selective regimen reduced infections in older adults · Weeks of dosing around vaccination
Mostly mechanism / observational9 studies

Steady research

33 studies in the last 5 years · Latest meta-analysis: 2021

200820172026

1Meta-Analysis2015

Tang CY, Shen A, Wei XF, Li QD, Liu R, Deng HJ · Hepatobiliary Pancreat Dis Int (2015)

Everolimus Research

Mostly mechanism / observational

Everolimus in de novo liver transplant recipients: a systematic review.

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.

Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis.

Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.

Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials.

Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis .

Everolimus plus endocrine vs endocrine therapy in treatment advanced ER+, HER2- breast cancer patients: A meta-analysis.

Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.

Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.

Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis.

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.

Rapamycin and rapalogs for tuberous sclerosis complex.

Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials.

Safety and Efficacy of Two Different Doses of Everolimus in Kidney Transplantation: a Systematic Review and Meta-Analysis.

Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.

177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.

Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.

Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.

Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.